Amgen’s biosimilar was approved in Europe under the Bekemv brand name last year and competes in the EU with the Samsung Bioepis rival sold as Epysqli. Samsung Bioepis has also filed for approval ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Hosted on MSN2mon
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?Amgen expects to launch two new three biosimilar products, Wezlana, a biosimilar to J&J’s JNJ Stelara, Bekemv, a biosimilar to Alexion’s Soliris in the first half of 2025. Pavblu (ABP 938), a ...
Amgen is also preparing to launch its Stelara biosimilar, called Wezlana, in the U.S. in the first quarter of 2025. The U.S. launch of its Soliris biosimilar, named Bekemv, is expected to follow ...
Amgen provided 2025 guidance ... with new launches expected in 2025, including BEKEMV (biosimilar to SOLIRIS). Product sales rose 19% year-over-year, driven by 23% volume growth.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback